Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
paul matteis
2
×
abbvie
acorda therapeutics
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
aminolevulinic acid
ampyra
apokyn
apomorphine
boston
dalfampridine
drugs
duopa
fda
givosiran
inbrija
mylan
national top stories
new york
new york blog main
new york top stories
onpattro
parkinson's disease
patisiran
rna interference
stiel
stifel financial
sunovion pharmaceuticals
What
drug
fda
2
×
nod
acorda
ago
alnylam
approval
approved
cope
disease
episodes
friday
gets
help
indicated
interference
late
looms
meant
medications
medicine
new
parkinson’s
patients
pharmaceuticals
quick
rival
rna
rnai
second
seek
speedy
stop
treatment
weeks
won’t
working
Language
Current search:
fda
×
" paul matteis "
×
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug